Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Theoretical and route-specific risks FDA's 2024 review specifically flagged that no published human exposure data exists for the subcutaneous, transdermal, or intranasal routes that compounding pharmacies have offered
Comparative studies in obese mice showed that AOD-9604 produced slightly greater fat reduction than the unmodified fragment at equivalent doses
This is why sourcing diligence and independent verification matter for research-grade material
Research suggests this may be due to higher concentrations of beta-3 adrenergic receptors in these fat depots
US$ 21.31
US$ 21.45
US$ 28.70
